ArticleBMC infectious diseases2025
Prevalence of serum HBV markers and management of occupational exposure to HBV among healthcare workers in a tertiary hospital.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHBV is the primary blood-borne pathogen of occupational exposure among healthcare workers (HCWs) in China. This study aims to analyze the characteristics of occupational exposure to HBV, and the ultimate goal is to optimize post-exposure management strategies for medical personnel.
methodsData of serum HBV markers (HBV-M) from a routine physical examination of HCWs in 2022 were retrieved, and characteristics of HBV-M were analyzed. Registration information of HBV occupational exposure from 2018 to 2022 was collected, and related risk factors were analyzed. HCWs injected with hepatitis B immunoglobulin (HBIG) were followed up.
results4,419 HCWs underwent physical examination, and there were nine patterns of HBV-M identified. HBsAg positive rate was 1.54%, and anti-HBs positive rate was 65.6%. There were 161 HBV occupational exposure incidents with no cases of HBV infection. Among categories of related factors for occupational exposure, occupation as a nurse, work experience < 5 years, sharp instruments as disposable needles, places of exposure as general wards, and operational processes as during surgical procedures were risk factors accounting for the highest proportion, respectively. 36 individuals received HBIG injection after exposure. One month after HBIG injection, the anti-HBs non-responder group at baseline showed low anti-HBs titers, which turned negative three months later.
conclusionsHBsAg positive rate is relatively low among HCWs, while anti-HBs positive rate is slightly higher than that of the general population. The management and control of major exposure factors should be strengthened. One month after HBIG injection might be the optimal timing for catch-up vaccination of hepatitis B vaccine. CLINICAL
trial registrationThis study does not involve any clinical trials. Clinical trial number is not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.